Physician profile
Todd J Rasner
NPI 1336148964
$2,567.80
in general payments reported to CMS, 2019-2025
35 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $260 · 2021: $340 · 2022: $477 · 2023: $319 · 2024: $189 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $412.27 | 2019-2025 | |
| Hologic Sales and Service, LLC | $305.39 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $254.05 | 2019-2025 | |
| Therapeuticsmd, INC. | $227.86 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $140.48 | 2022-2025 | |
| Abbvie INC. | $135.41 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $115.41 | 2023-2025 | Myfembree |
| Pfizer INC. | $110.83 | 2019-2024 | |
| Millicent US INC | $88.95 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Shield Therapeutics INC | $78.68 | 2023-2025 | Accrufer |
| Lupin INC. | $65.56 | 2019-2020 | |
| Lilly USA, LLC | $65.19 | 2024-2025 | Zepbound |
| Coloplast Corp | $53.29 | 2022-2023 | Saffron |
| Exeltis, USA INC. | $41.50 | 2021-2025 | Slynd |
| Amag Pharmaceuticals, INC. | $39.50 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $37.78 | 2022 | |
| Duchesnay USA Incorporated | $35.94 | 2019 | |
| Endo Pharmaceuticals INC. | $35.08 | 2020 | |
| Covidien LP | $34.85 | 2019-2020 | |
| Astellas Pharma US INC | $33.24 | 2021-2025 | Veozah |
| Virtus Pharmaceuticals LLC | $31.84 | 2022 | |
| Agile Therapeutics, INC. | $29.38 | 2021-2023 | Twirla |
| Avion Pharmaceuticals | $26.14 | 2019-2020 | |
| Horizon Therapeutics Plc | $22.10 | 2019 | |
| Solventum Corporation | $19.99 | 2025 | Prevena |
| Vivus LLC | $18.00 | 2021 | |
| Organon LLC | $17.84 | 2022 | |
| Allergan, INC. | $15.93 | 2019 | |
| Myovant Sciences INC. | $15.04 | 2022 | |
| Scynexis, INC. | $14.90 | 2022 | |
| Exact Sciences Corporation | $12.69 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $12.43 | 2020 | |
| Minerva Surgical, INC | $12.35 | 2019 | |
| Channel Medsystems, INC. | $7.91 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Rasner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.